The Smoker's Paradox Revisited: A Patient-Level Pooled Analysis of 18 Randomized Controlled Trials
- PMID: 31521646
- DOI: 10.1016/j.jcin.2019.06.034
The Smoker's Paradox Revisited: A Patient-Level Pooled Analysis of 18 Randomized Controlled Trials
Abstract
Objectives: This study examined the smoker's paradox using patient-level data from 18 prospective, randomized trials of patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
Background: Studies on the effects of smoking and outcomes among patients undergoing PCI have reported conflicting results.
Methods: Data from the RAVEL, E-SIRIUS, SIRIUS, C-SIRIUS, TAXUS IV and V, ENDEAVOR II to IV, SPIRIT II to IV, HORIZONS-AMI, COMPARE I and II, PLATINUM, and TWENTE I and II randomized trials were pooled. Patients were stratified by smoking status at time of enrollment. The 1- and 5-year ischemic outcomes were compared.
Results: Among 24,354 patients with available data on smoking status, 6,722 (27.6%) were current smokers. Smokers were younger and less likely to have diabetes mellitus; hypertension; hyperlipidemia; or prior myocardial infarction (MI), PCI, or coronary artery bypass grafting. Angiographically, smokers had longer lesions, more complex lesions, and more occlusions, but were less likely to have moderate or severe calcification or tortuosity. At 5 years, smokers had significantly higher rates of MI (7.8% vs. 5.6%; p < 0.0001) and definite or probable stent thrombosis (3.5% vs. 1.8%; p < 0.0001); however, there were no differences in the rates of death, cardiac death, target lesion revascularization, or composite endpoints (cardiac death, target vessel MI, or ischemic target lesion revascularization). After multivariable adjustment for potential confounders, smoking was a strong independent predictor of death (hazard ratio [HR]: 1.86; 95% confidence interval [CI]: 1.63 to 2.12; p < 0.0001), cardiac death (HR: 1.68; 95% CI: 1.38 to 2.05; p < 0.0001), MI (HR: 1.38; 95% CI: 1.20 to 1.58; p < 0.0001), stent thrombosis (HR: 1.60; 95% CI: 1.28 to 1.99; p < 0.0001), and target lesion failure (HR: 1.17; 95% CI: 1.05 to 1.30; p = 0.005).
Conclusions: The present large, patient-level, pooled analysis with 5-year follow-up clearly demonstrates smoking to be an important predictor of adverse outcomes after PCI.
Keywords: coronary artery disease; coronary artery disease outcomes; smokers; smoker’s paradox.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
The "Smoker's Paradox": The Closer You Look, the Less You See.JACC Cardiovasc Interv. 2019 Oct 14;12(19):1951-1953. doi: 10.1016/j.jcin.2019.07.028. Epub 2019 Sep 11. JACC Cardiovasc Interv. 2019. PMID: 31521650 No abstract available.
Similar articles
-
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005. JACC Cardiovasc Interv. 2013. PMID: 24050859
-
Smoking Status at Baseline and 10-Year Outcomes After Drug-Eluting Stent Implantation: Insights From the DECADE Cooperation.JACC Cardiovasc Interv. 2025 Apr 28;18(8):1001-1010. doi: 10.1016/j.jcin.2024.12.028. Epub 2025 Mar 19. JACC Cardiovasc Interv. 2025. PMID: 40117400
-
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901. doi: 10.1016/j.jcin.2016.06.022. JACC Cardiovasc Interv. 2016. PMID: 27659564
-
Drug-eluting stents versus coronary artery bypass grafting for left-main coronary artery disease.Catheter Cardiovasc Interv. 2018 Mar 1;91(4):697-709. doi: 10.1002/ccd.27235. Epub 2017 Aug 11. Catheter Cardiovasc Interv. 2018. PMID: 28799701 Review.
-
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.J Am Coll Cardiol. 2018 Jul 24;72(4):386-398. doi: 10.1016/j.jacc.2018.04.071. J Am Coll Cardiol. 2018. PMID: 30025574
Cited by
-
Patient-Related Factors Predicting Stent Thrombosis in Percutaneous Coronary Interventions.J Clin Med. 2023 Nov 28;12(23):7367. doi: 10.3390/jcm12237367. J Clin Med. 2023. PMID: 38068419 Free PMC article. Review.
-
Association between smoking status and outcomes in myocardial infarction patients undergoing percutaneous coronary intervention.Sci Rep. 2021 Mar 19;11(1):6466. doi: 10.1038/s41598-021-86003-w. Sci Rep. 2021. PMID: 33742073 Free PMC article.
-
Carbon monoxide and prognosis in smokers hospitalised with acute cardiac events: a multicentre, prospective cohort study.EClinicalMedicine. 2024 Jan 3;67:102401. doi: 10.1016/j.eclinm.2023.102401. eCollection 2024 Jan. EClinicalMedicine. 2024. PMID: 38261914 Free PMC article.
-
[[Long-term prognostic impact of the left anterior descending coronary artery as the STEMI-related culprit vessel: subanalysis of the EXAMINATION-EXTEND trial]].REC Interv Cardiol. 2025 Jan 29;7(2):99-108. doi: 10.24875/RECIC.M24000491. eCollection 2025 Apr-Jun. REC Interv Cardiol. 2025. PMID: 40438646 Free PMC article. Spanish.
-
Effect of Donor Cigarette Smoking in Kidney Transplantation: Re-Evaluation of Long-Term Outcomes.Transpl Int. 2024 Jun 24;37:12955. doi: 10.3389/ti.2024.12955. eCollection 2024. Transpl Int. 2024. PMID: 38979119 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous